TheraRadar
Clinical-Stage Companies / Opus Genetics

Opus Genetics

Pre-Approval PRO BETA
16
Total Trials
8
Phase 3
8
Phase 2
4
Recruiting
198
Score

Pipeline by Phase

Phase 3
8
Phase 2
8
Phase 1
3

Therapeutic Focus

Mydriasis Dilation Presbyopia ARB BVMD

Clinical Trials (16)

NCT07140783 Phase 3 RECRUITING

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Started: 9/2/2025

NCT06349759 Phase 3 COMPLETED

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

Started: 4/1/2024

NCT06542497 Phase 3 COMPLETED

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Started: 8/15/2024

NCT05646719 Phase 3 COMPLETED

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Started: 12/22/2022

NCT04638660 Phase 3 COMPLETED

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Started: 12/30/2020

NCT04620213 Phase 3 COMPLETED

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Started: 11/18/2020

NCT05223478 Phase 3 COMPLETED

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

Started: 12/17/2021

NCT05134974 Phase 3 COMPLETED

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Started: 11/18/2021

NCT04675151 Phase 2 COMPLETED

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Started: 2/15/2021

NCT03960866 Phase 2 COMPLETED

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Started: 5/28/2019

NCT04024891 Phase 2 COMPLETED

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Started: 8/13/2019

NCT04692688 Phase 2 COMPLETED

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Started: 4/8/2021

NCT01703559 Phase 2 COMPLETED

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Started: 9/9/2011

NCT07185256 Phase 1 RECRUITING

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Started: 9/25/2025

NCT05616793 Phase 1 RECRUITING

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Started: 6/15/2023

NCT07681778 Phase 1 RECRUITING

Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

Started: 10/1/2026

Drug Candidates

phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist 0.75% phentolamine ophthalmic solution Phentolamine Opthalmic Solution 0.75% Low dose pilocarpine AAV8.hLCA5 Phentolamine Ophthalmic Solution 0.75% Phentolamine Ophthalmic Solution Vehicle (Placebo) Pilocarpine 0.75% Phentolamine Ophthalmic Solution Phentolamine Mesylate Ophthalmic Solution 1%
Activity Status: Active
Last Trial Started: 10/1/2026
Last Trial Ended: 2/19/2026
Trials (12 months): 1
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.